Boch, C.; Reschke, M.; Igney, F.; Maier, P.; Müller, P.; Danklmaier, S.; Das, K.; Hofer, T.; Wollmann, G.; Rist, W.
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines 2022, 10, 2146.
https://doi.org/10.3390/biomedicines10092146
AMA Style
Boch C, Reschke M, Igney F, Maier P, Müller P, Danklmaier S, Das K, Hofer T, Wollmann G, Rist W.
Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines. 2022; 10(9):2146.
https://doi.org/10.3390/biomedicines10092146
Chicago/Turabian Style
Boch, Christina, Markus Reschke, Frederik Igney, Peter Maier, Philipp Müller, Sarah Danklmaier, Krishna Das, Tamara Hofer, Guido Wollmann, and Wolfgang Rist.
2022. "Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96" Biomedicines 10, no. 9: 2146.
https://doi.org/10.3390/biomedicines10092146
APA Style
Boch, C., Reschke, M., Igney, F., Maier, P., Müller, P., Danklmaier, S., Das, K., Hofer, T., Wollmann, G., & Rist, W.
(2022). Evaluating Antibody Pharmacokinetics as Prerequisite for Determining True Efficacy as Shown by Dual Targeting of PD-1 and CD96. Biomedicines, 10(9), 2146.
https://doi.org/10.3390/biomedicines10092146
